L&G Pharma Breakthrough UCITS ETF (EUR) | BIOTRegistrati per vedere i rating |
Storico dei rendimenti | 31/10/2024 |
Crescita di 1000 (EUR) | Grafico Interattivo |
Sintesi | ||
Prezzo di chiusura 20/11/2024 | EUR 9,667 | |
Var.Ultima Quotazione | 1,21% | |
Categoria Morningstar™ | Azionari Settore Biotecnologia | |
Volume | 1107 | |
Borsa | BORSA ITALIANA S.P.A. | |
Isin | IE00BF0H7608 | |
Fund Size (Mil) 21/11/2024 | USD 16,78 | |
Share Class Size (Mil) 21/11/2024 | USD 16,78 | |
Spese correnti 14/02/2024 | 0,49% |
Obiettivo d'Investimento Dichiarato: L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT |
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position. |
Rendimenti % (EUR) | ||||||||||
|
Gestione | ||
Nome del Gestore Inizio Gestione | ||
- - | ||
Data di Partenza 18/01/2018 |
Pubblicità |
Indice | |
Benchmark Dichiarato | Indice di Categoria Morningstar |
Solactive Pharma Breakthrough V NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Composizione del Fondo L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT | 20/11/2024 |
|
|
Primi 5 Titoli | Settore | % |
Pharma Mar SA | Salute | 4,91 |
InnoCare Pharma Ltd | Salute | 3,69 |
Agios Pharmaceuticals Inc | Salute | 3,58 |
Xeris Biopharma Holdings Inc | Salute | 3,46 |
Bristol-Myers Squibb Co | Salute | 3,37 |
Incremento Decremento Nuova Posizione | ||
L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT |